COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews

Sun, Hong; Bu, Fengjiao; Li, Ling; Zhang, Xiuwen; Yan, Jin; Huang, Tao‐Min

doi:10.3389/fpubh.2022.1072137

Cited by 4 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with cancer are recommended for boosters as well. 8 After the second dose, there is still disagreement on the vaccine's efficacy. A fourth dose is advised because the already-established immunity is still underwhelming.…”

Section: Discussionmentioning

confidence: 99%

“…The ability of cancer cases to establish immunity against severe acute respiratory syndrome coronavirus 2 has been found to be enhanced by receiving a third dosage of the vaccine, according the current study. 8 Consideration should be given to the mRNA vaccine, which among a variety of vaccine types has the best immunogenicity. The booster immunization using the mRNA vaccine should be helpful in terms of preventive oncology given the current state of the outbreak and the future guidelines on immunizing a patient with an underlying cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The third dosage of the vaccination for patients who have malignancy is the topic for further discussion right now in clinical oncology. [6][7][8][9][10][11] According to some recent clinical trial findings, [12][13][14][15] the third vaccination dose may be beneficial. Increased immunity is usually observed after the third dose immunization, and there is no significant increase in the incidence of postvaccination adverse events.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

Yasri,

Wiwanitkit

2024

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) immunization frequently requires two standard doses. Due to the likelihood that the population may lose immunity after receiving a standard mass vaccination and the potential for the introduction of a new strain, several scientists are currently advocating the use of a booster dosage of the vaccine.The authors of this retrospective study used a clinical model for immune response prediction to forecast how solid cancer patients will respond to the fourth dosage of the COVID-19 immunization. In the case of homologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and messenger ribonucleic acid (mRNA) COVID-19 vaccines for vaccinees with underlying solid tumor are equal to 11.5 and 16.5%, respectively. In the event of heterologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and mRNA COVID-19 vaccines are equal to 2.2 and 7.2%, respectively, for patients with underlying solid cancer. In conclusion, the fourth dose of the COVID-19 vaccine regimen had an effect on the immunogenicity of vaccine recipients with underlying malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

Yasri,

Wiwanitkit

2024

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Several systematic reviews including a great number of studies have already shown that COVID-19 vaccines are effective and safe in patients with chronic diseases, such as malignancies, immune-mediated inflammatory disease, and immunocompromised patients. 5–9 Moreover, evidence from studies including individuals with cardiovascular disease supports the safety and effectiveness of COVID-19 vaccines in this population group. 10,11 That is, the Heart Failure Association of the European Society of Cardiology and the American Heart Association suggest COVID-19 vaccination as soon as possible to individuals with heart failure, heart disease, heart attack, and cardiovascular risk factors since they are high risk groups to develop COVID-19 outcomes.…”

Section: Introductionmentioning

confidence: 98%

COVID-19-related burnout reduces COVID-19 vaccination intention in cardiac patients: a cross-sectional study in Greece

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: New SARS-CoV-2 variants have emerged and COVID-19 is still a public health issue, especially for vulnerable groups such as people with chronic medical conditions. Objective: To investigate the impact of COVID-19-related burnout on COVID-19 vaccination intention in cardiac patients. Moreover, we investigated other possible demographic and psychological predictors of vaccination intention in cardiac patients. Methods: We conducted a cross-sectional study in Greece using a convenience sample. Data collection was performed from 20 November 2022 to 10 January 2023. We measured demographic data, COVID-19-related burnout, anxiety, depression, social support, and resilience. We used the following valid tools: COVID-19 burnout scale, Patient Health Questionnaire-4, Multidimensional Scale of Perceived Social Support, and Brief Resilience Scale. Results: Among patients, 45.8% were willing to accept a COVID-19 booster dose, 25.3% were hesitant, and 28.9% were unwilling. Patients experienced moderate levels of COVID-19-related burnout. After multivariable linear regression analysis, we found that increased age and decreased emotional exhaustion due to COVID-19 were associated with increased vaccination intention. Moreover, patients who have already received a booster dose had also a greater willingness to accept a new booster dose. Conclusions: Identification of factors that influence patients decision to accept a COVID-19 booster dose is crucial to maintain a high vaccination coverage rate among them in order to avoid COVID-19-related outcomes. Since a COVID-19 booster dose on an annual basis seems to be necessary policy makers should develop and implement vaccination programmes tailored for patients.

show abstract

“…for whom vaccination was available as of June 2021. Specifically, patients in Colombia have had access to different alternatives: the chemically inactivated vaccine, CoronaVac, designed to be administered in two doses and with a seroconversion rate greater than 90% 9 ; Two vaccines with viral vector technology, ChAdOx1 nCoV-19, with a two-dose schedule and reported efficacy between 62 and 90% 10 ; Ad26.COV2.S, proposed for an initial one-dose schedule, with a reported percentage of seroconversion from 80 to 100% 8 ; And finally, two vaccines with nucleic acid technology encoding a protein antigen, BNT162b2 12 , 13 , and mRNA-1273 14 , 15 , both to be administered initially in two-dose regimens and with reported seroconversion percentages of 100%.…”

Section: Introductionmentioning

confidence: 99%

Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study: Real world evidence from one Latin American country

Ospina¹,

Brugés²,

Triana³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Introduction: During the pandemic, it has been recommended that vaccination against COVID-19 be a priority for patients with cancer; however, these patients were not included in the initial studies evaluating the available vaccines. Objective: To define the impact of vaccination against COVID-19 in preventing the risk of complications associated with the infection in a cohort of patients with cancer in Colombia. Methods: An analytical observational cohort study, based on national registry of patients with cancer and COVID 19 infection ACHOC-C19, was done. The data was collected from June 2021, until October 2021. Inclusion criteria were: Patients older than 18 years with cancer diagnosis and confirmed COVID-19 infection. Data from the unvaccinated and vaccinated cohorts were compared. Outcomes evaluated included all-cause mortality within 30 days of COVID-19 diagnosis, hospitalization, and need for mechanical ventilation. The estimation of the effect was made through the relative risk (RR), the absolute risk reduction (ARR) and the number needed to treat (NNT). Multivariate analysis was performed using generalized linear models. Results : 896 patients were included, of whom 470 were older than 60 years (52.4%) and 59% were women (n=530). 172 patients were recruited in the vaccinated cohort and 724 in the non-vaccinated cohort (ratio: 1 to 4.2). The cumulative incidence of clinical outcomes among the unvaccinated vs vaccinated patients were: for hospitalization 42% (95% CI: 38.7%-46.1%) vs 29%; (95% CI: 22.4%-36.5%); for invasive mechanical ventilation requirement 8.4% (n=61) vs 4.6% (n=8) and for mortality from all causes 17% (n=123) vs 4.65% (n=8). Conclusion: In our population, unvaccinated patients with cancer have an increased risk of complications for COVID -19 infection, as hospitalization, mechanical ventilation, and mortality. It is highly recommended to actively promote the vaccination among this population.

show abstract

COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews

Cited by 4 publications

References 44 publications

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

COVID-19-related burnout reduces COVID-19 vaccination intention in cardiac patients: a cross-sectional study in Greece

Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study: Real world evidence from one Latin American country

Contact Info

Product

Resources

About